Company news

Aclaris Therapeutics, Inc. news in 2025

Aclaris Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)

December 18, 2025

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

November 24, 2025

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 5, 2025

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

October 28, 2025

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025

September 29, 2025

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress

September 8, 2025

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

August 26, 2025

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 6, 2025

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

July 28, 2025

Aclaris Therapeutics Announces Leadership Transition

July 27, 2025

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

June 29, 2025

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

June 25, 2025

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

June 22, 2025

Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

June 1, 2025

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

May 27, 2025

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

May 8, 2025

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 7, 2025

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

April 28, 2025

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

April 21, 2025

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

March 3, 2025

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

February 26, 2025

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

February 11, 2025

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

January 29, 2025

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

January 5, 2025

Decks in 2025